Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865436 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00865436: Completed Phase 1 study, sponsored by Actavis.
NCT00865436 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00865436, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is compare the relative bioavailability of 5 mg Glyburide/500 mg Metformin Hydrochloride Tablets by Alpharma with that of 5 mg/500 mg CLUCOVANCE® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult volunteers administered under fasting conditions.
Interventions
- DRUG Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
- DRUG CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-04 |
| Phase | Phase 1 |
What the finished NCT00865436 record still lists
NCT00865436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg is the first listed.
NCT00865436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00865436 about?
NCT00865436 is a clinical study titled "A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions". The purpose of this study is compare the relative bioavailability of 5 mg Glyburide/500 mg Metformin Hydrochloride Tablets by Alpharma with that of 5 mg/500 mg CLUCOVANCE® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult volunteers admini...
What is the current status of trial NCT00865436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-04. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00865436?
The interventions under investigation include: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg (DRUG), CLUCOVANCE® 5 mg/500 mg Tablets, single dose (DRUG).
Who is sponsoring clinical trial NCT00865436?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00865436's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia